Author:
Fernández María Pérez,Piteiro Bermejo Ana Belén,Peña Esparragoza Jessy Korina,Martínez Ana Blasco,Moreno Irene Aracil,Ramos Javier Mancha,Barrio Fuensanta Moreno
Reference8 articles.
1. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017;Smith;Br J Dermatol,2017
2. Anti-cytokine therapy for psoriasis – not only TNF-α blockers. Overview of reports on the effectiveness of therapy with IL-12/IL-23 and T and B lymphocyte inhibitors;Wcisło-Dziadecka;Postepy Hig Med Dosw (Online),2016
3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1);Leonardi;Lancet,2008
4. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up;Langley;Br J Dermatol,2015
5. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders;Benson;MAbs,2011
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献